This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gibson, K. Articles by O'Bryant, C. L Search for Related Content PubMed PubMed Citation Articles by Gibson, K. Articles by O'Bryant, C. L Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Breast Cancer Cancer Chemotherapy Osteoporosis Social Bookmarking                         What's this?

Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors

Department of Pharmacy, Rose Medical Center, Denver, CO

Cindy L O'Bryant, PharmD

Department of Clinical Pharmacy, School of Pharmacy C238-L15, University of Colorado Denver, Aurora, CO, Cindy.OBryant{at}UCDenver.edu

Objective. Breast cancer patients are at an increased risk of osteoporosis due to age, cancer, chemotherapy, and aromatase inhibitor therapy. This retrospective review determined if patients treated with aromatase inhibitors received appropriate screening and management for osteoporosis.

Design. University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied. Data was collected for each patient from the time of breast cancer diagnosis up to April 2007. The study endpoints included (1) appropriate screening for osteoporosis, (2) incidence of osteoporosis diagnosis, and (3) initiation of appropriate drug therapy for bone loss. Appropriate management was defined as adherence to the 2003 American Society of Clinical Oncology guidelines for bone health issues in women with breast cancer.

Results. Of the 54 patients included in this study, 12 (22.2%) had no DEXA scans documented, 22 (40.7%) patients received a baseline DEXA scan and 8 (14.8%) patients received baseline and yearly DEXA scans. During the study timeline, 26 (48%) patients were diagnosed with osteopenia and 4 (7%) patients were diagnosed with osteoporosis. Forty-one (75.9%) patients received calcium and vitamin D therapy. Bisphosphonate therapy was received by less than one-third of the osteopenic patients and three-fourths of the osteoporotic patients.

Conclusions. The majority of patients were not adequately screened which may have falsely lowered the diagnosis of osteoporosis resulting in omission of drug therapy. All high-risk patients should receive calcium and vitamin D therapy and be evaluated for bisphosphonate therapy. Screening and medical management for osteoporosis in breast cancer patients on aromatase inhibitors is an important area for clinical intervention. J Oncol Pharm Practice (2008) 14: 139—145.

Key Words: osteoporosis • bone mineral density • aromatase inhibitor • anastrozole • exemestane • letrozole • breast cancer

Journal of Oncology Pharmacy Practice, Vol. 14, No. 3, 139-145 (2008)
DOI: 10.1177/1078155208091866


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?